TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03555500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non fasting
Description: Non fasting group is allowed for clear fluids and food up to the time of the procedure.
Study: NCT03569566

Intervention type: OTHER
Intervention: Age, Genes, Training, Tickbourne Disease and Endurance
Description: Testing of genes, exosomes, physiological variables, tick-bourne disease markers, observation of training modality and performance
Study: NCT03658785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -5 to -1: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days
Study: NCT02227563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: repetitive daily tDCS sessions for a period of one week

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: control
Study: NCT04273113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Difficulties in Emotional Regulation Scale, Five Facet Mindfulness Questionnaire, Becks Depression and Becks Anxiety
Description: Patients asked to complete these 4 questionnaires pre, during and post biofeedback training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV Biofeedback (Healing Rhythms)
Description: Sensors placed on fingers to capture heart rate and skin temperature
Study: NCT00245466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given as a subcutaneous injection once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given as a subcutaneous injection once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given as a subcutaneous injection once every 4 weeks.
Study: NCT00188279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimum Dose Computed Tomography (MnDCT) scan
Description: Minimum Dose Computed Tomography (MnDCT) scan at regular follow up intervals for up to 5 years post-operatively.
Study: NCT01445730

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: 3 month fructose diet 75 g/day
Study: NCT04056806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin 1Mg Powder for Conventional Release Solution for Injection Vial
Description: efficacy comparison between 2 days and 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin 1Mg Powder for Conventional Release Solution for Injection Vial
Description: efficacy comparison between 2 days and 5 days
Study: NCT02604784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) fixed repeated dose
Description: An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Standard dosage of drugs for each PIPAC: Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m²) or Oxaliplatin (92 mg/m²) The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters into the air-waste system of the hospital.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) increasing single dose
Description: An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Escalating dosage of drugs for PIPAC: Cisplatin + Doxorubicin (from 15 mg/m² + 3 mg/m² to 100 mg/m² + 30 mg/m²) or Oxaliplatin (from 92 mg/m² to 300mg/m²).The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters.
Study: NCT01954706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Exercise
Description: Structured and supervised aerobic and resistance training 2 times per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
Study: NCT04760080

Intervention type: OTHER
Intervention: pre-treatment data
Description: We will evaluate in all patients pre-treatment data :~* Melanoma staging at treatment initiation~* Melanoma characteristics at initial diagnosis~* Number and location of metastasis~* Performans status~* Demographic information

Intervention type: OTHER
Intervention: during study treatment
Description: We will evaluate in all patients during study treatment :~* Rate of adverse events~* Type of adverse events~* Radiological response to treatment by CTscans that are routinely performed every three months.
Study: NCT03711786

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic implementation package
Description: The basic implementation package will involve identifying an internal coordinator who is one of the full-time on-site providers at the clinic. The internal coordinator provides mentoring to peers and support to leadership in implementing the treatment program and aligning it with clinic priorities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced implementation package
Description: The enhanced implementation package will combine the internal coordinator with an external quality assurance committee. This committee will complete quarterly audits at the facility to evaluate compliance with the depression treatment protocol as well as providing high-level support in implementing the treatment program through clinical expertise and limited on-site presence.
Study: NCT00843765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture, massage and basic TCM treatment
Description: 1. During hospitalization:Patients accept TCM rehabilitation and basic treatment including WM basic treatment and Chinese medicine injection,decoction,herb soak treatment and health education.~2. After discharge from hospital: In the TCM group,add prescriptions according to two conditions:a. patients using A injection (one Chinese herb injection admitted by SFDA) will take A' capsule (one Chinese herb capsule admitted by SFDA) for 6 months;b.patients using B injection (ditto) will take B' capsule (ditto) for 6 months.Both of them will accept TCM health education.In the WM group, patients are suggested with targeted rehabilitation programs according to different causes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation and WM basic treatment
Description: there two steps:~1. during hospitalization: patients accept modern rehabilitation and basic treatment of life supporting and medicine using and health education~2. After discharge: make rehabilitation plans for patients including management of anticoagulant drugs, blood pressure, blood lipid and blood glucose, health education, and some suggestions for resisting alcohol ,smoking and reasonable diet
Study: NCT04387565

Intervention type: OTHER
Intervention: magnesium and vanadium measurements and compare
Description: Magnesium and vanadium will be measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).
Study: NCT00140738

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' 719125
Description: Patients receive six vaccinations at two-week intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' 719125
Description: Patients receive six vaccinations at two-week intervals
Study: NCT04387565

Intervention type: OTHER
Intervention: magnesium and vanadium measurements and compare
Description: Magnesium and vanadium will be measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).

Intervention type: OTHER
Intervention: magnesium and vanadium measurements and compare
Description: Magnesium and vanadium will be measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).
Study: NCT00038402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Starting dose of 4 mg/kg by vein, then 2 mg/kg weekly after that until the end of all cycles of neo-adjuvant chemotherapy and during FEC therapy for a total of 24 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: 225 mg/m\^2 by vein as a continuous infusion over 24 hours each cycle for a total of 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 500 mg/m\^2 by vein on Days 1 and 4 for 4 cycles at 3-4 week intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: 500 mg/m\^2 on Day 1 of each cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 75 mg/m\^2 IV on Day 1 of each cycle for 4 cycles.
Study: NCT04125147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Montage Bone Hemostat
Description: Use of Montage bone hemostat on the cut surfaces of bone at the osteotomy site
Study: NCT04054765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: videogame
Description: Invite Only VR videogame

Intervention type: OTHER
Group type: OTHER
Intervention: treatment as usual
Description: treatment as usual
Study: NCT00864630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based problem solving therapy
Description: Computer program developed by Dr. James Cartriene at Beth Israel Deaconess Hospital, Boston, MA.
Study: NCT01434095

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: half-dose photodynamic therapy
Description: photodynamic therapy (PDT) was performed using 3 mg/m2 body surface area of verteporfin (Visudyne, Novartis AG, Bülach, Switzerland) which is one-half the conventional dose of verteporfin. The verteporfin was infused over a 10 minute period followed by the delivery of 50 J/cm2 from a 689-nm laser system (Carl Zeiss, Dublin, CA) over an 83-second exposure time.
Study: NCT02932501

Intervention type: PROCEDURE
Intervention: Conservative treatment
Description: Disinfectant mouth rinses, Antibiotic therapy, Antifungal therapy

Intervention type: PROCEDURE
Intervention: Surgical treatment
Description: Superficial debridement, Complete removal of necrotic bone, Complete bone resection, When applicable revision and soft tissue coverage

Intervention type: PROCEDURE
Intervention: Adjuvant non-surgical treatment
Description: Hyperbaric oxygen therapy Pentoxifylline and tocopherol Ozone therapy Low level laser therapy Pain relief Anti-inflammatory treatment Platelet rich plasma Parathyroid hormone and teriparatide Bone morphogenetic protein
Study: NCT02092376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01707160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 30
Description: One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin 30
Description: One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
Study: NCT03154983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Diagnosed with metastatic gastric cancer patients (including the esophagogastric junction adenocarcinoma), DS(docetaxel and Tegafur)and Mesylate apatinib 6 cycles, the specific amount of usage: DS Docetaxel 75mg/m2 D1 IV.drop 1H（one hour）, Tegafur(BSA\<1.25 40mg Po bid(twice a day), BSA \>=1.25-\<1.5 50mg Po bid, BSA \>=1.5 60mg Po bid, Q21d(21 days a cycle)); Mesylate Apatinib 500mg Po QD（once a day)） continuous use, until disease deterioration.
Study: NCT01566188

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 from vegetal origin
Description: 6 months of supplementation with omega-3 from vegetal origin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 months of supplementation with placebo
Study: NCT02720328

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples for DOAC measurement
Study: NCT02688543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RF treatment
Description: the genicular nerves are identified with the help of landmarks, ultrasound and nerve stimulation. Once the needle is correctly placed high frequency current is passed through the probe during 90 seconds at 20 V with tip temperature put to 80°C.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Study: NCT04003883

Intervention type: DEVICE
Intervention: Holter ECG
Description: A Holter ECG will be recorderd during shifts
Study: NCT00739882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efalizumab - anti CD11a recombinant human monoclonal antibody
Description: Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week. The treatment period will be 24 weeks divided into two phases: 1) double-blind for 12 weeks, and 2) open-label for 12 additional weeks, in which all subjects from the placebo group and those subjects from the Raptiva ® group with ≥ 50% of improvement will be allocated to extended treatment with Raptiva ® for 12 additional weeks while non-responders to Raptiva ® (improvement ≤ 50%) will be followed in an observational manner for 12 additional weeks without treatment.
Study: NCT03137758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCUR - 101
Description: PCUR-101 Capsules 25 mg are solid dosage forms for oral administration
Study: NCT00739882

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered at Study Day (SD) 1, Week (W) 1, W 4, W 8 and W 12. Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week for 12 weeks (double-blind phase)
Study: NCT03006601

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Office-based accommodative/vergence therapy
Description: Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 12 weeks) and home reinforcement (15 minutes each time, five times per week, 12 weeks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Office-based accommodative/vergence therapy
Description: Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 12 weeks) and home reinforcement (15 minutes each time, five times per week, 12 weeks)
Study: NCT02544620

Intervention type: OTHER
Intervention: Does fulfil of discharge criteria on the day of the surgery

Intervention type: OTHER
Intervention: Does fulfil of discharge criteria on the day of the surgery

Intervention type: OTHER
Intervention: Does fulfil of discharge criteria on the day of the surgery

Intervention type: OTHER
Intervention: Does not fulfil of discharge criteria on the day of the surgery

Intervention type: OTHER
Intervention: Does not fulfil of discharge criteria on the day of the surgery

Intervention type: OTHER
Intervention: Does not fulfil of discharge criteria on the day of the surgery
Study: NCT03412136

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants were given 5 minutes to ingest the non-caloric beverage which contained 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water and sweetened with 0.2g sucralose (Tate \& Lyle, Stoney Creek, Ontario, Canada) in order to match sweetness with the glucose beverage.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Participants were given 5 minutes to ingest the beverage which contained either 1g of protein (plain whey-protein isolate; BiPro USA., Eden Prairie, Minnesota, U.S.A) per kg of bodyweight and was flavoured with 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Participants were given 5 minutes to ingest the beverage which contained 1g of glucose monohydrate (BioShop Canada Inc., Burlington, Ontario, Canada) per kg of bodyweight and flavoured with 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water.
Study: NCT03775525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ17-6.02
Description: Super enhancer Inhibition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ17-6.02
Description: Super enhancer Inhibition
Study: NCT03137758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCUR - 101
Description: PCUR-101 Capsules 25 mg are solid dosage forms for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCUR - 101
Description: PCUR-101 Capsules 25 mg are solid dosage forms for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCUR - 101
Description: PCUR-101 Capsules 25 mg are solid dosage forms for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCUR - 101
Description: PCUR-101 Capsules 25 mg are solid dosage forms for oral administration
Study: NCT03775525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ17-6.02
Description: Super enhancer Inhibition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: antimetabolite
Study: NCT00884481

Intervention type: OTHER
Intervention: Natalizumab
Description: Participants treated with Tysabri
Study: NCT03049124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will engage in supervised exercise 3 times per week for 60-75 minutes/session for 12 weeks. Sessions will include a warm-up (aerobic activity less than \< 60% of heart rate reserve), aerobic training (30 minutes of exercise at 60-75% of heart rate reserve, using cycle ergometers/treadmills), strength training (8 exercises; upper body, lower body, and core), and a cool-down (aerobic activity less than \< 60% of heart rate reserve) component.
Study: NCT01659918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Study: NCT03775525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: antimetabolite
Study: NCT01659918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Singulair
Study: NCT01963104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No screening test/Motivational video
Description: This group of subjects will not receive a screening test. They will watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home Hearing Screening Test
Description: Subjects will be taught the set-up for a home hearing screening test and will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
Study: NCT00671281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Oral form, 100mg, tid (three times per day), 3 days before/the day of/6 days after the surgery
Study: NCT01963104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home Hearing Screening Test/Brief video
Description: Subjects will be taught the set-up for a home hearing screening test and will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss.~Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
Study: NCT03055676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early drain removal
Description: Removing drain(s) on postoperative day 3

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late drain removal
Description: Removing drain(s) on postoperative day 5 or later